Ask Warren

HK inno.N

195940 · KOSDAQ · ₩195940 · HK이노엔

₩34,650▼ ₩50 (0.14%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −29.07%
Market cap
₩982B
Enterprise value
₩1.3T
P/E
11.4×
P/B
0.7×
Dividend yield
1.2%
ROE
6.4%
Net margin
8.0%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−40.9% from the high

₩32,600Today: ₩33,450 – ₩34,700₩58,600

Returns

  • 1W+1.6%
  • 1M−12.6%
  • 3M−0.7%
  • 6M−33.9%
  • YTD−29.7%
  • 1Y−29.1%
Volume today
98,924
1.0× the 20-day average
Traded today
₩3.4B
Listed shares
28,329,891
EPS (12 months)
₩3,030
Earnings yield 8.7%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

43Quiet
  • BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
  • MomentumWeak-11.7% over the last month; the price is below its 20-day average.
  • News impactSome10 news items and filings in two weeks; 0 rated high impact, 1 medium.
  • StreetSteady2 brokers, average target 77% from the price; last 30 days: 0 raised, 0 cut.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩289M at the close (7.9% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 14 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 31.4% of trading value and pointed the same way 12 of 14 times.

  • 2× KODEX KOSDAQ150 Leverage −₩201M
  • -1× KODEX KOSDAQ150 Futures Inverse −₩50M
  • 2× TIGER KOSDAQ150 Leverage −₩25M
  • 2× RISE KOSDAQ150 Futures Leverage −₩9.5M
  • -1× TIGER KOSDAQ150 Futures Inverse −₩1.6M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 34,550

Basis −0.29% · implied rate −7.5%

Open interest 4,552 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

HK inno.N stock overview

HK inno.N (HK이노엔, KRX: 195940) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells prescription drugs (ETC) and health and beverage (H&B) products. Its shares closed at ₩34,650 on Oct 29, 2026, down 0.14% on the day, giving it a market value of ₩982B.

Key facts

Market cap
₩982B
Sector
Biotech & Pharma
Latest price change
−0.14%
As of
Oct 29, 2026
Main business
The company develops, manufactures and sells prescription drugs (ETC) and health and beverage (H&B) products.

Quick answers about HK inno.N

What does HK inno.N do?
The company develops, manufactures and sells prescription drugs (ETC) and health and beverage (H&B) products. Its key prescription drugs include Cabbage-based acid reducer K-CAB, Lovaziet and Akinzeo, along with IV fluids, while its H&B lineup includes Condition hangover drink, Hutgaesu and Be Wants skincare. The company operates in South Korea, with its drugs also marketed in China, the United States, India and South America, and prescription drugs account for about 93% of total sales.
What is the market cap of HK inno.N?
The market capitalisation of HK inno.N was ₩982B at the close on Oct 29, 2026.
What is the analyst target price for HK inno.N?
The average target price of 2 brokers covering HK inno.N is ₩61,500 (range ₩55,000 to ₩68,000), 77.5% above versus the latest price, based on each broker's latest public report within six months.
Who are the largest shareholders of HK inno.N?
According to the latest official filings, the largest reported holders are Korea Kolmar (43.14%, as of Apr 22, 2026); National Pension Service (5.03%, as of Oct 2, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.77%, as of Jul 31, 2026).
When is the next earnings report from HK inno.N?
Korean companies rarely announce results dates in advance. Based on when HK inno.N filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own HK inno.N?
Yes. The National Pension Service held 5.03% of HK inno.N shares as of Oct 2, 2026.

Company profile

The company develops, manufactures and sells prescription drugs (ETC) and health and beverage (H&B) products. Its key prescription drugs include Cabbage-based acid reducer K-CAB, Lovaziet and Akinzeo, along with IV fluids, while its H&B lineup includes Condition hangover drink, Hutgaesu and Be Wants skincare. The company operates in South Korea, with its drugs also marketed in China, the United States, India and South America, and prescription drugs account for about 93% of total sales.

Written by AI from the company's latest annual report.

Korean name
HK이노엔
Sector
Biotech & Pharma
Themes
Obesity drugsPharmaceuticals
Business group
Kolmar
CEO
곽달원
Founded
Apr 2014
Listed
Aug 2021
Listed shares
28,329,891
Fiscal year ends
Month 12
Website
www.inno-n.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: HK inno.N / HK이노엔 / 195940 / KRX:195940

Source: KRX statistical information